ArticleNeurology research international2012
Novel therapies in glioblastoma.
Article in Neurology research international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 51 citations in OpenAlex.
- Optical coherence tomography (OCT) and OCT angiography: Technological development and applications in brain science.Theranostics · 2025Review
- Design, synthesis, and biological activity of dual monoamine oxidase A and heat shock protein 90 inhibitors, N-Methylpropargylamine-conjugated 4-isopropylresorcinol for glioblastoma.European journal of medicinal chemistry · 2023Article
- Mechanical Properties of the Extracellular Environment of Human Brain Cells Drive the Effectiveness of Drugs in Fighting Central Nervous System Cancers.Brain sciences · 2022Review
- OCT-Guided Surgery for Gliomas: Current Concept and Future Perspectives.Diagnostics (Basel, Switzerland) · 2022Review
- SOX transcription factors and glioma stem cells: Choosing between stemness and differentiation.World journal of stem cells · 2021Review
- Strategies to better treat glioblastoma: antiangiogenic agents and endothelial cell targeting agents.Future medicinal chemistry · 2021Review
- Integrated genetic and metabolic landscapes predict vulnerabilities of temozolomide resistant glioblastoma cells.NPJ systems biology and applications · 2021Article
- Investigation of cellular effects of thymoquinone on glioma cell.Toxicology reports · 2021Article
- Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme.Drug delivery and translational research · 2020Review
- Tumor image-derived texture features are associated with CD3 T-cell infiltration status in glioblastoma.Oncotarget · 2017Article
- VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties.Neuro-oncology · 2017Article
- ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.Neuro-oncology · 2017Article
- Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma.Annals of translational medicine · 2016Review
- Colchicine derivative as a potential anti-glioma compound.Journal of neuro-oncology · 2015Article
- A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.BMC cancer · 2015Article
- Perspectives in Intraoperative Diagnostics of Human Gliomas.Computational and mathematical methods in medicine · 2015Review
- Engineering a High-Throughput 3-D In Vitro Glioblastoma Model.IEEE journal of translational engineering in health and medicine · 2015Article
- Combining targeted agents with modern radiotherapy in soft tissue sarcomas.Journal of the National Cancer Institute · 2014Review
- Radiosynthesis of [18F]ATPFU: a potential PET ligand for mTOR.Journal of labelled compounds & radiopharmaceuticals · 2014Article
- Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional treatment of glioblastoma has advanced only incrementally in the last 30 years and still yields poor outcomes. The current strategy of surgery, radiation, and chemotherapy has increased median survival to approximately 15 months. With the advent of molecular biology and consequent improved understanding of basic tumor biology, targeted therapies have become cornerstones for cancer treatment. Many pathways (RTKs, PI3K/AKT/mTOR, angiogenesis, etc.) have been identified in GBM as playing major roles in tumorigenesis, treatment resistance, or natural history of disease. Despite the growing understanding of the complex networks regulating GBM tumors, many targeted therapies have fallen short of expectations. In this paper, we will discuss novel therapies and the successes and failures that have occurred. One clear message is that monotherapies yield minor results, likely due to functionally redundant pathways. A better understanding of underlying tumor biology may yield insights into optimal targeting strategies which could improve the overall therapeutic ratio of conventional treatments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.